JP2007533722A - トリ（シクロ）置換アミド化合物 - Google Patents

トリ（シクロ）置換アミド化合物 Download PDF

Info

Publication number
JP2007533722A
JP2007533722A JP2007508982A JP2007508982A JP2007533722A JP 2007533722 A JP2007533722 A JP 2007533722A JP 2007508982 A JP2007508982 A JP 2007508982A JP 2007508982 A JP2007508982 A JP 2007508982A JP 2007533722 A JP2007533722 A JP 2007533722A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
compound
fluorothiazol
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007508982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533722A5 (enExample
Inventor
マシュー・ファイフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of JP2007533722A publication Critical patent/JP2007533722A/ja
Publication of JP2007533722A5 publication Critical patent/JP2007533722A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007508982A 2004-04-21 2005-04-19 トリ（シクロ）置換アミド化合物 Withdrawn JP2007533722A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56417104P 2004-04-21 2004-04-21
US60107704P 2004-08-12 2004-08-12
PCT/GB2005/050053 WO2005103021A1 (en) 2004-04-21 2005-04-19 Tri(cyclo) substituted amide compounds

Publications (2)

Publication Number Publication Date
JP2007533722A true JP2007533722A (ja) 2007-11-22
JP2007533722A5 JP2007533722A5 (enExample) 2008-06-19

Family

ID=34965439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508982A Withdrawn JP2007533722A (ja) 2004-04-21 2005-04-19 トリ（シクロ）置換アミド化合物

Country Status (15)

Country Link
US (1) US20080242869A1 (enExample)
EP (1) EP1740560A1 (enExample)
JP (1) JP2007533722A (enExample)
KR (1) KR20060134179A (enExample)
AU (1) AU2005235798A1 (enExample)
BR (1) BRPI0510163A (enExample)
CA (1) CA2563192A1 (enExample)
EA (1) EA012204B1 (enExample)
IL (1) IL178473A0 (enExample)
MA (1) MA28545B1 (enExample)
MX (1) MXPA06012008A (enExample)
NO (1) NO20065260L (enExample)
NZ (1) NZ550567A (enExample)
WO (1) WO2005103021A1 (enExample)
ZA (1) ZA200608489B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133687A1 (ja) * 2008-04-28 2009-11-05 杏林製薬株式会社 シクロペンチルアクリル酸アミド誘導体

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2005113713A (ru) 2002-10-03 2006-01-20 Новартис АГ (CH) Замещенные (тиазол-2-ил)амиды или сульфонамиды в качестве активаторов глюкокиназы, которые могут применяться при лечении диабета типа 2
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2005095417A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
ATE524479T1 (de) 2004-04-02 2011-09-15 Novartis Ag Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
AU2005271016A1 (en) * 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
BRPI0622261A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
RU2008112198A (ru) 2005-09-29 2009-10-10 Санофи-Авентис (Fr) Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
BRPI0715531A2 (pt) 2006-07-24 2014-06-24 Hoffmann La Roche Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008111473A1 (ja) * 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
KR20100113518A (ko) 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
WO2009140624A2 (en) 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
CN102245574A (zh) * 2008-12-08 2011-11-16 欧洲筛选有限公司 用于治疗代谢疾病的化合物、药物组合物以及方法
UA104742C2 (uk) 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
JP2013522294A (ja) 2010-03-18 2013-06-13 タケダ カリフォルニア インコーポレイテッド ２−アミノ−５−フルオロチアゾールの製造プロセス

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
CN1151140C (zh) * 1999-03-29 2004-05-26 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
EP1282611B1 (en) * 2000-05-08 2004-10-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
ATE297907T1 (de) * 2000-07-20 2005-07-15 Hoffmann La Roche Alpha-acyl- und alpha-heteroatom-substituierte benzenacetamide verwendbar als glucokinase- aktivatoren
JP4109111B2 (ja) * 2000-12-06 2008-07-02 エフ．ホフマン−ラ ロシュ アーゲー 縮合複素環式芳香族グルコキナーゼアクチベーター
WO2003095438A1 (en) * 2002-04-26 2003-11-20 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133687A1 (ja) * 2008-04-28 2009-11-05 杏林製薬株式会社 シクロペンチルアクリル酸アミド誘導体
JP5449144B2 (ja) * 2008-04-28 2014-03-19 杏林製薬株式会社 シクロペンチルアクリル酸アミド誘導体
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체

Also Published As

Publication number Publication date
NO20065260L (no) 2006-11-21
EA012204B1 (ru) 2009-08-28
NZ550567A (en) 2010-07-30
MA28545B1 (fr) 2007-04-03
WO2005103021A1 (en) 2005-11-03
BRPI0510163A (pt) 2007-10-02
US20080242869A1 (en) 2008-10-02
EA200601747A1 (ru) 2007-04-27
AU2005235798A1 (en) 2005-11-03
CA2563192A1 (en) 2005-11-03
MXPA06012008A (es) 2007-01-25
ZA200608489B (en) 2008-06-25
IL178473A0 (en) 2007-02-11
EP1740560A1 (en) 2007-01-10
KR20060134179A (ko) 2006-12-27

Similar Documents

Publication Publication Date Title
JP2007533722A (ja) トリ（シクロ）置換アミド化合物
US7214681B2 (en) Tri(cyclo) substituted amide compounds
JP4621198B2 (ja) トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
KR100890695B1 (ko) 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
JP2006517590A5 (enExample)
CN1427830A (zh) 对－胺基取代的苯基酰胺葡糖激酶激活剂
JP2009514837A (ja) グルコキナーゼ調節物質としてのトリシクロ置換アミド
JP2009514836A (ja) トリシクロ置換型アミド
CN100567276C (zh) 三（环）取代的酰胺类化合物
HK1082507B (en) Phenylacetamides and their use as glucokinase modulators
HK1082507A1 (en) Phenylacetamides and their use as glucokinase modulators
CN101296908A (zh) 作为葡糖激酶调节剂的三环取代的酰胺

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080417

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110131